RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
500 participants
Feb 1, 2024
OBSERVATIONAL
Conditions
Summary
RADIOSPHER2 study is a monocentric, retrospective, observational study aiming at identifying a radiomics signature able to predict HER2 expression (0 vs low vs overexpression) and trastuzumab deruxtecan efficacy in metastatic breast cancer patients. The study also encompasses translational analyses and inter-modal correlations in order to provide novel insights about HER2 spatial and temporal heterogeneity, at the macroscopic and microscopic levels.
Eligibility
Inclusion Criteria1
- Patients with metastatic breast cancer underwent a liver, lung, pleural or bone biopsy in the metastatic setting, performed from 01Jan2005 to 01Jan2024.
Exclusion Criteria3
- Not available imaging (CT scan and/or PET-FdG scan) in the three months before the biopsy or before the last previous treatment interruption;
- Unknown HER2 status;
- Node, soft tissue or other visceral as biopsy site.
Interventions
A subgroup of the study cohort treated with Trastuzumab Deruxtecan in the metastatic setting
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07030569